Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IART 
Integra LifeSciences Holdings (IART)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: IART (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -62% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 925.55M USD | Price to earnings Ratio - | 1Y Target Price 16.12 |
Price to earnings Ratio - | 1Y Target Price 16.12 | ||
Volume (30-day avg) 1325070 | Beta 1.17 | 52 Weeks Range 11.59 - 32.66 | Updated Date 06/22/2025 |
52 Weeks Range 11.59 - 32.66 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -1.78% | Operating Margin (TTM) 8.23% |
Management Effectiveness
Return on Assets (TTM) 2.66% | Return on Equity (TTM) -1.86% |
Valuation
Trailing PE - | Forward PE 5.17 | Enterprise Value 2646327255 | Price to Sales(TTM) 0.56 |
Enterprise Value 2646327255 | Price to Sales(TTM) 0.56 | ||
Enterprise Value to Revenue 1.63 | Enterprise Value to EBITDA 14.68 | Shares Outstanding 77712304 | Shares Floating 61777372 |
Shares Outstanding 77712304 | Shares Floating 61777372 | ||
Percent Insiders 14.22 | Percent Institutions 96.54 |
Analyst Ratings
Rating 2.92 | Target Price 16.12 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold 5 | Sell 2 | Strong Sell 2 | |
Strong Sell 2 |
Upturn AI SWOT
Integra LifeSciences Holdings
Company Overview
History and Background
Integra LifeSciences was founded in 1989. It focuses on developing and marketing surgical implants and medical instruments. Significant milestones include product launches, acquisitions, and global expansion.
Core Business Areas
- Codman Specialty Surgical (CSS): Offers solutions for neurosurgery, including advanced surgical instruments and implants for brain and spine procedures.
- Tissue Technologies: Focuses on regenerative medicine and advanced wound care products using collagen-based technology and skin grafts.
Leadership and Structure
The leadership team includes Jan De Witte (President & CEO). The organizational structure is divided by business segments, with functional support departments.
Top Products and Market Share
Key Offerings
- Competitors: Medtronic (MDT),Johnson & Johnson (JNJ)
- DuraGen: A dural repair graft matrix used in neurosurgical procedures. Competitors include Medtronic (MDT) and Johnson & Johnson (JNJ). Market share data is not publicly available for this single product.
- CUSA: An ultrasonic surgical aspirator used for tissue ablation. Competitors include Sonacare Medical and Misonix (now part of Stryker SYK). Market share data is not publicly available for this single product.
- Competitors: Sonacare Medical,Stryker (SYK)
- Competitors: Smith & Nephew (SNN),Mu00f6lnlycke Health Care AB
- Integra Bilayer Matrix Wound Dressing: Used for wound care. Competitors include Smith & Nephew (SNN) and Mu00f6lnlycke Health Care AB. Market share data is not publicly available for this single product.
Market Dynamics
Industry Overview
The medical device industry is driven by innovation, aging populations, and increased healthcare spending. It's highly regulated and competitive.
Positioning
Integra LifeSciences is positioned as a key player in neurosurgery and advanced wound care, with a focus on innovative technologies and specialized products.
Total Addressable Market (TAM)
The neurosurgery and wound care markets are estimated to be worth billions of dollars. Integra holds a significant share but has ample room for growth.
Upturn SWOT Analysis
Strengths
- Strong portfolio of established products
- Innovative technology platform
- Global distribution network
- Focus on specialized surgical solutions
Weaknesses
- Reliance on acquisitions for growth
- High debt levels
- Dependence on key product lines
- Integration challenges post-acquisition
Opportunities
- Expanding into emerging markets
- Developing new products and indications
- Capitalizing on increasing demand for minimally invasive surgery
- Strategic partnerships and collaborations
Threats
- Intense competition from larger medical device companies
- Regulatory changes and pricing pressures
- Technological advancements rendering existing products obsolete
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Johnson & Johnson (JNJ)
- Stryker (SYK)
- Smith & Nephew (SNN)
Competitive Landscape
Integra LifeSciences competes with larger, more diversified medical device companies. It focuses on niche markets and specialized products to maintain a competitive edge.
Major Acquisitions
Acquired Company Name
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded product portfolio and market reach in the wound care segment.
Growth Trajectory and Initiatives
Historical Growth: Integra's growth has been a mix of organic and acquisition-driven, with focus on expanding existing product lines and entering new markets.
Future Projections: Analysts project continued growth in the single digits, driven by new product launches and market expansion.
Recent Initiatives: Recent initiatives include acquisitions, product launches and strategic partnerships. Specific details need to be filled in based on the latest data.
Summary
Integra LifeSciences is a mid-sized medical device company with a strong presence in neurosurgery and wound care. Their growth strategy relies on acquisitions and innovation. They face competition from larger players and must manage debt effectively. Despite some challenges, Integra is positioned for continued growth in specialized markets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Investor Presentations
- Analyst Reports
- Industry Research Reports
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice, and investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Integra LifeSciences Holdings
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 1995-08-16 | President, CEO & Director Ms. Mojdeh Poul | ||
Sector Healthcare | Industry Medical Devices | Full time employees 4396 | Website https://www.integralife.com |
Full time employees 4396 | Website https://www.integralife.com | ||
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company addresses the needs of plastic, and reconstructive and general surgeons focused on the treatment of acute wounds, such as burns and chronic wounds, including diabetic foot ulcers; and provides surgical tissue repair products for hernia, tendon, peripheral nerve repair, and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. Further, it is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.